Caprock Group’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.7M | Buy |
25,651
+2,198
| +9% | +$405K | 0.11% | 153 |
|
|
2025
Q4 | $4.13M | Buy |
23,453
+17,842
| +318% | +$2.91M | 0.09% | 192 |
|
|
2025
Q3 | $742K | Buy |
+5,611
| New | +$758K | 0.02% | 669 |
|
|
2025
Q1 | – | Sell |
-2,007
| Closed | -$307K | – | 1087 |
|
|
2024
Q4 | $307K | Sell |
2,007
-1,111
| -36% | -$187K | 0.01% | 792 |
|
|
2024
Q3 | $604K | Buy |
3,118
+437
| +16% | +$91.4K | 0.02% | 516 |
|
|
2024
Q2 | $622K | Sell |
2,681
-255
| -9% | -$55.4K | 0.03% | 483 |
|
|
2024
Q1 | $633K | Sell |
2,936
-2,577
| -47% | -$604K | 0.04% | 352 |
|
|
2023
Q4 | $1.43M | Buy |
5,513
+427
| +8% | +$105K | 0.09% | 183 |
|
|
2023
Q3 | $1.31M | Sell |
5,086
-276
| -5% | -$73.8K | 0.1% | 163 |
|
|
2023
Q2 | $1.53M | Buy |
5,362
+95
| +2% | +$28.3K | 0.11% | 144 |
|
|
2023
Q1 | $1.46M | Buy |
5,267
+135
| +3% | +$37.4K | 0.11% | 145 |
|
|
2022
Q4 | $1.42M | Buy |
5,132
+200
| +4% | +$56.5K | 0.13% | 121 |
|
|
2022
Q3 | $1.32M | Sell |
4,932
-81
| -2% | -$17.2K | 0.13% | 120 |
|
|
2022
Q2 | $1.02M | Buy |
5,013
+578
| +13% | +$118K | 0.1% | 155 |
|
|
2022
Q1 | $934K | Buy |
4,435
+120
| +3% | +$26.1K | 0.09% | 185 |
|
|
2021
Q4 | $1.03M | Sell |
4,315
-212
| -5% | -$54.5K | 0.09% | 170 |
|
|
2021
Q3 | $1.28M | Buy |
4,527
+234
| +5% | +$76.7K | 0.11% | 125 |
|
|
2021
Q2 | $1.49M | Sell |
4,293
-321
| -7% | -$97.2K | 0.14% | 117 |
|
|
2021
Q1 | $1.29M | Buy |
4,614
+2
| +0% | +$539 | 0.14% | 118 |
|
|
2020
Q4 | $1.13M | Sell |
4,612
-83
| -2% | -$21.4K | 0.13% | 130 |
|
|
2020
Q3 | $1.33M | Buy |
4,695
+93
| +2% | +$25.9K | 0.18% | 101 |
|
|
2020
Q2 | $1.23M | Buy |
4,602
+18
| +0.4% | +$5.41K | 0.19% | 98 |
|
|
2020
Q1 | $1.45M | Buy |
4,584
+24
| +0.5% | +$7.28K | 0.27% | 73 |
|
|
2019
Q4 | $1.35M | Buy |
4,560
+36
| +0.8% | +$9.99K | 0.24% | 82 |
|
|
2019
Q3 | $1.05M | Sell |
4,524
-8
| -0.2% | -$1.86K | 0.21% | 94 |
|
|
2019
Q2 | $1.06M | Buy |
4,532
+1,296
| +40% | +$299K | 0.21% | 91 |
|
|
2019
Q1 | $765K | Buy |
3,236
+21
| +0.7% | +$6.61K | 0.15% | 122 |
|
|
2018
Q4 | $967K | Buy |
3,215
+24
| +0.8% | +$7.66K | 0.22% | 94 |
|
|
2018
Q3 | $1.13M | Buy |
3,191
+44
| +1% | +$15.1K | 0.23% | 83 |
|
|
2018
Q2 | $913K | Buy |
3,147
+74
| +2% | +$20.8K | 0.19% | 104 |
|
|
2018
Q1 | $841K | Sell |
3,073
-64
| -2% | -$19.9K | 0.18% | 109 |
|
|
2017
Q4 | $1.05M | Sell |
3,137
-16
| -0.5% | -$5.13K | 0.21% | 99 |
|
|
2017
Q3 | $987K | Buy |
3,153
+186
| +6% | +$55.1K | 0.21% | 94 |
|
|
2017
Q2 | $805K | Sell |
2,967
-49
| -2% | -$13K | 0.18% | 119 |
|
|
2017
Q1 | $825K | Buy |
3,016
+115
| +4% | +$32.5K | 0.19% | 97 |
|
|
2016
Q4 | $823K | Sell |
2,901
-785
| -21% | -$233K | 0.21% | 101 |
|
|
2016
Q3 | $1.15M | Buy |
3,686
+127
| +4% | +$37.6K | 0.26% | 90 |
|
|
2016
Q2 | $861K | Buy |
3,559
+426
| +14% | +$112K | 0.21% | 113 |
|
|
2016
Q1 | $816K | Buy |
+3,133
| New | +$828K | 0.19% | 116 |
|
Other funds holding BIIB
VCM
VPM
Caprock Group's BIIB Position: Q1 2026 in Review
Caprock Group increased its Biogen (BIIB) stake by 9.4% in Q1 2026, buying an estimated $405K and bringing the position to 25,651 shares worth $4.7M. The position accounts for 0.11% of the portfolio, ranked #153.
Caprock Group first reported a position in BIIB in Q1 2016 and has held it in 39 quarters since. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Caprock Group held 25,651 shares of Biogen worth $4.7M as of Q1 2026.
- Caprock Group bought 2,198 Biogen shares in Q1 2026, an estimated $405K.
- Biogen made up 0.11% of Caprock Group's portfolio in Q1 2026, its #153 holding.
- Caprock Group first reported a position in Biogen in Q1 2016 and has held it in 39 quarters since.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.